Skip to content

Ketamine research published in 2024

Page 22 of 26: studies 421 to 440 of 518, newest first. Back to the ketamine overview

Studies

Comparison of Dexmedetomidine and Ketamine in Serratus Anterior Plane Block for Postoperative Pain Control in Thoracotomy Patients: A Randomized Clinical Trial.

Anesthesiology and pain medicine February 1, 2024 Mahbobeh Rashidi, Kamran Mahmoodi, Reza Akhondzadeh et al. 3 citations

Postoperative pain control after thoracotomy is very important, and if not controlled, it can cause severe complications. This study aimed to compare dexmedetomidine and ketamine in serratus anterior plane block (SAPB) in pain control after thoracotomy. This randomized clinical trial was conducted on 74 patients aged 18 to 60 years old with American Society of Anesthesiologists (ASA) class I or...

DOI: 10.5812/aapm-137664 (opens in new tab) Full text (opens in new tab) Ketamine Dexmedetomidine Postoperative pain Thoracotomy +5

Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats

Nature Communications January 30, 2024 Tommaso Di Ianni, Sedona N. Ewbank, Marjorie R. Levinstein et al.

Subanesthetic ketamine is increasingly used for the treatment of varied psychiatric conditions, both on- and off-label. While it is commonly classified as an N -methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of subanesthetic ketamine may...

Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes

medRxiv Preprint Server January 30, 2024 Lauren N. Swanson, Lila S. Jones, Jose Muñoz Aycart et al. preprint

Objective To evaluate the effectiveness of repeated at-home ketamine treatments for depression, generalized anxiety, and social anxiety and assess safety in terms of adverse effects and tendency towards long-term use.

DOI: 10.1101/2024.01.30.24301798 (opens in new tab) Full text (opens in new tab) Mental health treatment Ketamine therapy Depression & anxiety Treatment efficacy +1

Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety

Frontiers in Psychiatry January 23, 2024 Johannes Hauser, Jan Sarlon, Timur Liwinski et al. 10 citations

BackgroundAlthough the effectiveness of (es)ketamine for therapy-resistant depression (TRD) has been established, potential treatment-limiting factors include side effects like dissociation, anxiety, or elevated blood pressure. Music can reduce stress and negative emotions as anxiety. This study aimed to investigate the impact of listening to music during intranasal (es)ketamine administration...

Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report

International Clinical Psychopharmacology January 22, 2024 L. Chevalier, Samuel Bulteau, L. Cheval et al.

Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted...

Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update

Canadian Journal of Health Technologies January 17, 2024 Angela M. Barbara, Weiyi Xie, Quenby Mahood et al. 4 citations

What Is the Issue? Many drug treatments are available for depression, but 22% of people in Canada with the condition have treatment-resistant depression (TRD). For people with TRD, standard drug treatments do not improve their symptoms or do not work for long, and their depression persists. Posttraumatic stress disorder (PTSD) is a disabling mental health condition that affects about 9% of...

Ketamine Produces Antidepressant Effects by Inhibiting Histone Deacetylases and Upregulating Hippocampal Brain-Derived Neurotrophic Factor Levels in a Diisopropyl Fluorophosphate-Based Rat Model of Gulf War Illness.

Journal of Pharmacology and Experimental Therapeutics January 17, 2024 Ana Ribeiro-Davis, Dalia Y Al Saeedy, Fay M Jahr et al. 10 citations

Approximately one-third of Gulf War veterans suffer from Gulf War Illness (GWI), which encompasses mood disorders and depressive symptoms. Deployment-related exposure to organophosphate compounds has been associated with GWI development. Epigenetic modifications have been reported in GWI veterans. We previously showed that epigenetic histone dysregulations were associated with decreased...

DOI: 10.1124/jpet.123.001824 (opens in new tab) Full text (opens in new tab) Ketamine therapy Neuroscience research Veterans health Depression treatment +1

Depression-like phenotypes in mice with hepatic ischemia/reperfusion injury: A role of gut-microbiota-liver-brain axis via vagus nerve.

Journal of Affective Disorders January 15, 2024 Yong Yang, Akifumi Eguchi, Xiayun Wan et al.

Depression is a frequent symptom in patients with chronic liver disease; however, the mechanisms underlying this association remain unclear. Dysbiosis of gut microbiota plays a critical role in depression through the gut-brain axis via the vagus nerve. In this study, we investigated whether the gut-microbiota-liver-brain axis plays a role in depression-like phenotypes in mice with hepatic...

Esketamine Prevents Postoperative Emotional and Cognitive Dysfunction by Suppressing Microglial M1 Polarization and Regulating the BDNF-TrkB Pathway in Ageing Rats with Preoperative Sleep Disturbance

Molecular Neurobiology January 15, 2024 Yuxin Wen, Jiawen Xu, Jiahong Shen et al. 57 citations

Postoperative depression (POD) and postoperative cognitive dysfunction (POCD) have placed heavy burden on patients’ physical and mental health in recent years. Sleep disturbance before surgery is a common phenomenon that has been increasingly believed to affect patients’ recovery, especially in aged patients, while little attention has been paid to sleep disruption before surgery and the...

Rapid-acting antidepressant drugs modulate affective bias in rats

Science Translational Medicine January 10, 2024 Katie Kamenish, Roberto Arban, Aslihan Selimbeyoglu et al. 26 citations

How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment....

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Current Neuropharmacology January 5, 2024 Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic et al. 73 citations

Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs))....

Antipsychotic effect of diosgenin in ketamine-induced murine model of schizophrenia: Involvement of oxidative stress and cholinergic transmission

IBRO Neuroscience Reports January 3, 2024 Benneth Ben-Azu, Olusegun G Adebayo, Aliance R Fokoua et al.

A decrease in the levels of antioxidant arsenals exacerbate generation of reactive oxygen/nitrogen species, leading to neurochemical dysfunction, with significant impact on the pathogenesis of psychotic disorders such as schizophrenia. This study examined the preventive and reversal effects of diosgenin, a phyto-steroidal saponin with antioxidant functions in mice treated with ketamine which...

Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression

Journal of Child and Adolescent Psychopharmacology January 3, 2024 Alice Lineham, Victor J. Avila‐quintero, Michael H. Bloch et al. 15 citations

Objective:Ketamine has proved effective as a rapid-acting antidepressant agent, but treatment is not effective for everyone (approximately a quarter to a half of patients). Some adult studies have begun to investigate predictors of ketamine's antidepressant response, but no studies have examined this in adolescents with depression. Methods:We conducted a secondary data analysis of adolescents...

Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report

BMC Psychiatry January 2, 2024 Minna Chang, Mario F Juruena, Allan H. Young 16 citations

Abstract Background Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage and can be seen in over 25% of regular users. Although...

A Meta-Analysis of Functional Neuroimaging Studies of Ketamine Administration in Healthy Volunteers.

Journal of Psychoactive Drugs 2024 Karim Ait Bentaleb, Mélanie Boisvert, Valérie Tourjman et al.

Ketamine administration leads to a psychotomimetic state when taken in large bolus doses, making it a valid model of psychosis. Therefore, understanding ketamine's effects on brain functioning is particularly relevant. This meta-analysis focused on neuroimaging studies that examined ketamine-induced brain activation at rest and during a task. Included are 10 resting-state studies and 23...

DOI: 10.1080/02791072.2023.2190758 (opens in new tab) Full text (opens in new tab) Ketamine Executive functions Functional imaging Meta-analysis +1

Ketamine in neuropsychiatric disorders: an update.

Neuropsychopharmacology January 2024 Jenessa N Johnston, Bashkim Kadriu, Christoph Kraus et al.

The discovery of ketamine as a rapid-acting antidepressant led to a new era in the development of neuropsychiatric therapeutics, one characterized by an antidepressant response that occurred within hours or days rather than weeks or months. Considerable clinical research supports the use of-or further research with-subanesthetic-dose ketamine and its (S)-enantiomer esketamine in multiple...

NEUROMODULATORY EFFECTS OF ESTRADIOL AND PROGESTERONE ON KETAMINE'S ACTION IN FEMALE RAT BRAIN

Proceedings of the Second Southern Science Conference. Book B 2024 N. González, P. Ramirez, Esther Berenice Vargas Hunger et al.

Ketamine-induced psychotic episodes with hallucinations and sensory dissociation when abused. In rats, prolonged intraperitoneal ketamine (K) administration increases locomotor activity. Neuroactive steroids modulate responses to such drugs. This study aimed to investigate ketamine-induced neuroadaptive effects and neuromodulatory phenomena from Estradiol (E2) and Progesterone (P4) in female...

Case series: Clinical response of ketamine infusion in patients with treatment-resistant depression

Telangana Journal of Psychiatry 2024 Pallavi Preetinanda, Srikrishna Nukala, Abhilash Garapati et al.

Treatment-resistant depression (TRD) is one of the most debilitating conditions that does not respond to conventional pharmacotherapy. Ketamine is a recently used effective treatment option in depressive disorders with a novel mechanism of action. Still, studies estimating the improvement of depressive symptoms in TRD with multiple doses of ketamine are limited. Hence, we report 5 TRD cases...